When inflammation in the body goes unchecked, it can cause fibrosis, or tissue scarring that may lead to organ dysfunction or ...

The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported. At week 24, the least squares mean ...

The growth of the Scleroderma Treatment Market is being propelled by the increasing prevalence of autoimmune disorders and heightened awareness of scleroderma among clinicians and patients. With the ...

The global systemic scleroderma treatment market expected to reach USD 2.2 billion by 2028 according to a new study by Report Ocean. The report “Systemic Scleroderma Treatment Market Report, By Drug ...

Sheffield Teaching Hospitals NHS Foundation Trust has become the only site in the UK to open a groundbreaking international ...

For the 300,000 Americans living with the immune disease scleroderma, better treatments can't come soon enough. The rare and sometimes fatal illness stiffens and scars tissue in organs like the lungs, ...

SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ...

Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook Design by Evelyn Mousigian. Dr. John Varga, rheumatology, internal medicine and dermatology ...

North Chicago biotech startup BLR Bio has received U.S. Food & Drug Administration Orphan Drug Designation for its investigational treatment for the rare disease systemic sclerosis. The drug, BLR-200, ...